Compare Bank of New York Mellon Corp (BNY) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Eli Lilly And Co — how do they compare? Bank of New York Mellon Corp trades at $161.35 (market cap $108.78B), while Eli Lilly And Co trades at $1,211 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 9.9× Bank of New York Mellon Corp's market cap, and Bank of New York Mellon Corp pays the higher dividend (1.38%). Which is the better fit depends on your goals.
| BNY | LLY | |
|---|---|---|
Market Cap | $108.78B | $1.08T |
Sector | Financials | Health |
52-Week High | $162.35 | $1.24K |
52-Week Low | $101.00 | $639.43 |
Dividend Yield | 1.38% | 0.57% |
Enterprise Value | — | $1.13T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY stock trades at $159.44, up 1.14% on the day, near the analyst consensus price target of $170.36. The stock shows a bullish technical trend with strong moving average signals, and fundamentals are robust with consistent earnings beats, revenue growth to $19.76B in 2025, and a net income margin of 29.96%. Recent news highlights strategic moves in digital asset infrastructure and a dividend declaration.
The outlook for BNY is positive, supported by earnings momentum and digital innovation, but risks include high investing cash outflows and interest expenses. Analyst sentiment is mixed with a slight hold bias, yet institutional upgrades and a strong ROE of 15.34% offer upside potential amid market volatility.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
